Literature DB >> 29404796

Continuous renal replacement therapy with a polymethyl methacrylate membrane hemofilter suppresses inflammation in patients after open-heart surgery with cardiopulmonary bypass.

Hiroshi Mukaida1,2, Satoshi Matsushita3, Takahiro Inotani2, Atsushi Nakamura4, Atsushi Amano1.   

Abstract

Cardiopulmonary bypass (CPB) induces a complex inflammatory response involving an increase in inflammatory cytokines, called postperfusion syndrome. Previous studies demonstrated that adsorption of the serum cytokines can reduce acute inflammation and improve clinical outcomes. In this study, patients were placed on continuous renal replacement therapy (CRRT) with a polymethyl methacrylate (PMMA) membrane hemofilter immediately after the start of an open-heart surgery with CPB and throughout the postoperative course to prevent postperfusion syndrome. The aim of this study was to assess whether continuous CRRT using a PMMA filter (PMMA-CRRT) could affect cytokine expression and improve perioperative outcomes. We designed a randomized controlled trial, which included 19 consecutive adult patients on maintenance dialysis and 7 consecutive adult patients who were not on maintenance dialysis (NHD group). Patients on maintenance dialysis were randomly divided into two groups: Ten patients who received CRRT with a polysulfone membrane hemofilter (PS group) and nine patients who received CRRT with a PMMA membrane (PMMA group). Blood samples were collected from the radial or brachial artery at five different time points. Comparisons between the PS, PMMA, and NHD groups revealed a significant main effect of time on changes in serum IL-6 and IL-8 concentrations (p < 0.01) and an interaction (p < 0.05) between time and group. Plasma IL-6 and IL-8 levels after surgery were significantly lower in the PMMA group than in the PS group, while other cytokines measured in this study were not significantly different. In addition, clinical outcomes were not significantly different between the groups. The continuous use of PMMA-CRRT throughout the perioperative period suppressed serum IL-6 and IL-8 concentrations, although there were no differences in clinical outcomes.

Entities:  

Keywords:  Cytokine; IL-6; IL-8; Postperfusion syndrome

Mesh:

Substances:

Year:  2018        PMID: 29404796     DOI: 10.1007/s10047-018-1025-6

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  33 in total

Review 1.  An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response.

Authors:  Kenneth G Shann; Donald S Likosky; John M Murkin; Robert A Baker; Yvon R Baribeau; Gordon R DeFoe; Timothy A Dickinson; Timothy J Gardner; Hilary P Grocott; Gerald T O'Connor; David J Rosinski; Frank W Sellke; Timothy W Willcox
Journal:  J Thorac Cardiovasc Surg       Date:  2006-08       Impact factor: 5.209

2.  Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase.

Authors:  Nazima Pathan; Joanne L Franklin; Hariklia Eleftherohorinou; Victoria J Wright; Cheryl A Hemingway; Simon J Waddell; Michael Griffiths; Jayne L Dennis; David A Relman; Sian E Harding; Michael Levin
Journal:  Crit Care Med       Date:  2011-07       Impact factor: 7.598

3.  Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass.

Authors:  J Steinberg; G Fink; A Picone; B Searles; H Schiller; H M Lee; G Nieman
Journal:  J Extra Corpor Technol       Date:  2001-12

4.  Continuous renal replacement therapy reduces the systemic and pulmonary inflammation induced by venovenous extracorporeal membrane oxygenation in a porcine model.

Authors:  Jialiang Shi; Qiyi Chen; Wenkui Yu; Juanhong Shen; Jianfeng Gong; Changsheng He; Yiming Hu; Juanjuan Zhang; Tao Gao; Fengchan Xi; Jieshou Li
Journal:  Artif Organs       Date:  2013-12-11       Impact factor: 3.094

5.  Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure.

Authors:  Kenichi Matsuda; Takeshi Moriguchi; Norikazu Harii; Junko Goto
Journal:  Transfus Apher Sci       Date:  2008-12-21       Impact factor: 1.764

6.  Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations.

Authors:  Y Sawa; Y Shimazaki; K Kadoba; T Masai; H Fukuda; T Ohata; K Taniguchi; H Matsuda
Journal:  J Thorac Cardiovasc Surg       Date:  1996-01       Impact factor: 5.209

7.  Timing of initiation of dialysis in critically ill patients with acute kidney injury.

Authors:  Kathleen D Liu; Jonathan Himmelfarb; Emil Paganini; T Alp Ikizler; Sharon H Soroko; Ravindra L Mehta; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-06       Impact factor: 8.237

8.  Effects of continuous renal replacement therapy on renal inflammatory cytokines during extracorporeal membrane oxygenation in a porcine model.

Authors:  Hu Yimin; Yu Wenkui; Shi Jialiang; Chen Qiyi; Shen Juanhong; Lin Zhiliang; He Changsheng; Li Ning; Li Jieshou
Journal:  J Cardiothorac Surg       Date:  2013-04-29       Impact factor: 1.637

9.  Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial.

Authors:  Juan J Jiménez; José L Iribarren; Maitane Brouard; Domingo Hernández; Salomé Palmero; Alejandro Jiménez; Leonardo Lorente; Patricia Machado; Juan M Borreguero; José M Raya; Beatriz Martín; Rosalía Pérez; Rafael Martínez; María L Mora
Journal:  J Cardiothorac Surg       Date:  2011-10-14       Impact factor: 1.637

Review 10.  Immunosuppression following surgical and traumatic injury.

Authors:  Fumio Kimura; Hiroaki Shimizu; Hiroyuki Yoshidome; Masayuki Ohtsuka; Masaru Miyazaki
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.